Equities research analysts at Leerink Partnrs decreased their Q4 2024 earnings estimates for shares of Mind Medicine (MindMed) in a research note issued on Wednesday, January 29th. Leerink Partnrs ...

Leerink Partnrs upped their FY2024 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...

Shares of Walgreens dove early Friday, a day after the drugstore chain said it was suspending its dividend, breaking a streak ...

(Reuters) -Walgreens Boots Alliance has suspended its quarterly cash dividend amid restructuring efforts, the U.S. pharmacy ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...